PharmIdea
Professional & Innovative

Dexmedetomidine Pharmidea

100 mcg/ml concentrate for solution for infusion available in 3 presentations:

- 200 mcg/2 ml
- 400 mcg/4 ml
- 1000 mcg/10 ml

Dexmedetomidine is highly selective α2-adrenergic receptor agonist approved in 1999 by the U.S. Food and Drug Administration (FDA) as sedative and analgesic agent and in 2004 approved by European Medicine Agency (EMA).

NEW GENERATION OF ANESTHETIC AGENTS

INDICATIONS

- Intensive Care Unit Sedation (ICU) indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.
- Procedural Sedation indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.

USAGE and CLINICAL ADVANTAGES

Dexmedetomidine is an anxiety reducing, sedative and analgesic agent indicated also for patient with cardiovascular diseases without risk of respiratory depression. It allows to lower the use of analgesics in postoperative period, provides memory-preserving sedation, helps suppress shivering and improves postoperative recovery.

ADMINISTRATION

Generally initiated with a loading dose at 0.7 to 1 mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour up to 24 hours.

CONCLUSIONS

Dexmedetomidine offers a unique ability of providing both sedation and analgesia without respiratory depression. It is a new agent with a wide safety margin, excellent sedative capacity and moderate analgesic properties.

ATC code: N05CM18
Storage condition: Store at room temperature 15 to 25° C
Stability studies: Climatic zones II; IV B; accelerated terms
Shelf life: 36 months
Manufacturer: PharmIdea SIA, 4 Rupnicu Str., Olaine, LV 2114, Latvia
pharmidea@pharmidea.lv

www.pharmidea.lv